APVO News and Press, Aptevo Therapeutics Inc. From 09/19/22

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types LUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") today anno...

Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of $5.58. Aptevo had cash, cash equivalents and restricted cash of $30 million as of June 30, 2022. For further details see: Aptevo Therapeutics GAAP EPS of $5.58

SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technolo...

DocuSign (DOCU) -25% on Q1 earnings release. RISE Education Cayman (REDU) -24%. Stitch Fix (SFIX) -15% on FQ3 earnings release. DBV Technologies (DBVT) -15%. Caribou Biosciences (CRBU) -13% amid new data for CAR-T therapy for non-Hodgkin lymphoma. Applied UV (AUV...

Aptevo Therapeutics (NASDAQ:APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase 1b expansion trial for lead candidate APVO436 in acute myeloid leukemia (AML). According to early data ...

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable an...

Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$1.59 misses by $0.66. Revenue of $3.11M (+28.5% Y/Y) misses by $0.64M. For further details see: Aptevo Therapeutics GAAP EPS of -$1.59 misses by $0.66, revenue of $3.11M misses by $0.64M

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologie...

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...

Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...